Developing irreversible inhibitors of the protein kinase cysteinome Q Liu, Y Sabnis, Z Zhao, T Zhang, SJ Buhrlage, LH Jones, NS Gray Chemistry & biology 20 (2), 146-159, 2013 | 755 | 2013 |
Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database PV Desai, A Patny, Y Sabnis, B Tekwani, J Gut, P Rosenthal, A Srivastava, ... Journal of medicinal chemistry 47 (26), 6609-6615, 2004 | 156 | 2004 |
Structure− activity relationships of the antimalarial agent artemisinin. 6. The development of predictive in vitro potency models using CoMFA and HQSAR methodologies MA Avery, M Alvim-Gaston, CR Rodrigues, EJ Barreiro, FE Cohen, ... Journal of medicinal chemistry 45 (2), 292-303, 2002 | 128 | 2002 |
Structure-based approach to falcipain-2 inhibitors: synthesis and biological evaluation of 1, 6, 7-trisubstituted dihydroisoquinolines and isoquinolines S Batra, YA Sabnis, PJ Rosenthal, MA Avery Bioorganic & medicinal chemistry 11 (10), 2293-2299, 2003 | 94 | 2003 |
Exploration of acyl sulfonamides as carboxylic acid replacements in protease inhibitors of the hepatitis C virus full-length NS3 R Rönn, YA Sabnis, T Gossas, E Ĺkerblom, U Helena Danielson, ... Bioorganic & medicinal chemistry 14 (2), 544-559, 2006 | 89 | 2006 |
Probing the structure of falcipain‐3, a cysteine protease from Plasmodium falciparum: Comparative protein modeling and docking studies YA Sabnis, PV Desai, PJ Rosenthal, MA Avery Protein Science 12 (3), 501-509, 2003 | 83 | 2003 |
Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls of post-filtering D Muthas, YA Sabnis, M Lundborg, A Karlén Journal of Molecular Graphics and Modelling 26 (8), 1237-1251, 2008 | 70 | 2008 |
Interaction of artemisinin and its related compounds with hydroxypropyl‐β‐cyclodextrin in solution state: Experimental and molecular‐modeling studies AC Illapakurthy, YA Sabnis, BA Avery, MA Avery, CM Wyandt Journal of pharmaceutical sciences 92 (3), 649-655, 2003 | 67 | 2003 |
Investigation of the effect of molecular properties on the binding kinetics of a ligand to its biological target DC Miller, G Lunn, P Jones, Y Sabnis, NL Davies, P Driscoll MedChemComm 3 (4), 449-452, 2012 | 65 | 2012 |
Evaluation of a diverse set of potential P< sub> 1</sub> carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors R Rönn, T Gossas, YA Sabnis, H Daoud, E Ĺkerblom, UH Danielson, ... Bioorganic & medicinal chemistry 15 (12), 4057-4068, 2007 | 65 | 2007 |
Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors P Örtqvist, SD Peterson, E Ĺkerblom, T Gossas, YA Sabnis, R Fransson, ... Bioorganic & medicinal chemistry 15 (3), 1448-1474, 2007 | 63 | 2007 |
Design and synthesis of a pan-Janus kinase inhibitor clinical candidate (PF-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of … P Jones, RI Storer, YA Sabnis, FM Wakenhut, GA Whitlock, KS England, ... Journal of Medicinal Chemistry 60 (2), 767-786, 2017 | 58 | 2017 |
Homology modeling of falcipain-2: validation, de novo ligand design and synthesis of novel inhibitors Y Sabnis, PJ Rosenthal, P Desai, MA Avery Journal of Biomolecular Structure and Dynamics 19 (5), 765-774, 2002 | 56 | 2002 |
Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II D Muthas, D Nöteberg, YA Sabnis, E Hamelink, L Vrang, B Samuelsson, ... Bioorganic & medicinal chemistry 13 (18), 5371-5390, 2005 | 47 | 2005 |
Pyrazolopyridines and pyrazolopyrimidines JW Coe, CM Dehnhardt, P Jones, YA Sabnis, JW Strohbach, ... US Patent 9,518,052, 2016 | 44 | 2016 |
The promise of AI for DILI prediction A Vall, Y Sabnis, J Shi, R Class, S Hochreiter, G Klambauer Frontiers in Artificial Intelligence 4, 638410, 2021 | 41 | 2021 |
Indazoles JW Coe, CM Dehnhardt, P Jones, SW Kortum, YA Sabnis, FM Wakenhut, ... US Patent 8,575,336, 2013 | 40 | 2013 |
A new structural theme in< i> C</i>< sub> 2</sub>-symmetric HIV-1 protease inhibitors:< i> ortho</i>-Substituted P1/P1′ side chains J Wannberg, YA Sabnis, L Vrang, B Samuelsson, A Karlén, A Hallberg, ... Bioorganic & medicinal chemistry 14 (15), 5303-5315, 2006 | 40 | 2006 |
Indazoles JW Coe, CM Dehnhardt, P Jones, SW Kortum, YA Sabnis, FM Wakenhut, ... US Patent App. 14/041,387, 2013 | 37 | 2013 |
Discovery and synthesis of a new class of opioid ligand having a 3-azabicyclo [3.1. 0] hexane core. An example of a ‘magic methyl’giving a 35-fold improvement in binding G Lunn, BJ Banks, R Crook, N Feeder, A Pettman, Y Sabnis Bioorganic & medicinal chemistry letters 21 (15), 4608-4611, 2011 | 34 | 2011 |